Breaking News

CMAB Biopharma, BJ Bioscience in Strategic Development and Mfg. Pact

CMAB will provide a full range of CMC research and manufacturing services to support IND applications for China and the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CMAB Biopharma (Suzhou) Inc., a biologics CDMO, and BJ Bioscience, an innovative biopharmaceutical company, have entered a strategic agreement for the development and manufacturing of a Bi-functional Antibody (BJ-005) as the first step in an exclusive collaboration.   CMAB will provide a full range of CMC research and manufacturing services to support the IND application requirements of both China and the U.S. The collaboration will support the clinical development of BJ-005 worldwide by BJ Bi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters